Scandinavian ChemoTech receives a final injunction from the European Patent Office
Scandinavian ChemoTech AB announces today that the Company has received a final injunction from the European Patent Office where the examiner announces that the patent for the Company's innovation, for TSE treatment of skeletal metastases and deep-seated tumours, will be granted.
The patent covers a specially developed electrode as well as unique dynamic properties, which already exist in the TSE platform, intended to treat tumours without damaging important parts of organs and tissues such as nerve pathways and blood vessels. This is of utmost importance in the treatment of, among other things, the spine and prostate.
This innovation provides improved pain control when using the Company's DEEPC (Dynamic Electro Enhanced Pain Control)™ device for IQwave™, for the delivery of electrical pulses to the desired body part.
“This injunction comes at a very opportune time after we completed a very successful issue and subscription through the warrants at the beginning of the week. We have now received a patent protection for our unique technology that makes TSE treatment possible even for deeper tumours and ChemoTech is now entering a new phase and will in the spring set our long-term clinical strategy, which will focus on treatment with a new indication with market focus on EU and North America. " - says Mohan Frick, CEO and author of this patent together with Prof B Persson
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 03-02-2021 15:30 CET.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.